Vapreotide Acetate

Detailed Product Description 98% Injectable Polypeptide Hormones Sanvar CAS 16941-32-5 Vapreotide Acetate For Treating Esophageal Variceal Bleeding Quick Details: • Vapreotide Acetate • Sequence: D-Phe-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2 • Alias:Sanvar,RC-160;VAPREOTIDE;D-PHE-CYS-TYR-D-TRP-LYS-VAL-CYS-TRP-NH2; Octastatin; • FCYWKVCW-NH2;D-Phe-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Trp-NH2; • Cas No.: 103222-11-3 • Molecular Formula: C57H70N12O9S2 • M.S.: • Molecular Weight: 1131.40 • Purity (HPLC): 98.0% • Appearance: White powder • Single Impurity(HPLC): 1.0% • Amino Acid Composition: 10% of theoretical • Peptide Content(N%): 80%(by %N) • Water Content(Karl Fischer): 6.0% • Acetate Content(HPIC): 15.0% • Mass Balance: 95.0~105.0% • Grade : Pharmaceutical Grade • Storage: Closed, below 2 ~ 8℃ preservation • Manufacturer : Hezhong • Usage : The drug can be used for treatment of early acute esophageal variceal bleeding (EVB) and endoscopic interventional therapy before hemostasis, can also be bleeding within 5 d lens for the treatment and prevention of recurrence after endoscopic.vapreotide acetate will be the only approved treatment for esophageal variceal bleeding in the United States.

Description: Variceal bleeding is a life-threatening complication of portal hypertension. The recommended treatment includes the early administration of a vasoactive drug. Vapreotide is a somatostatin analogue with a different receptor affinity to octreotide. It decreases portal pressure and blood flow of collateral circulation in rats with cirrhosis.

The pivotal study of early administration of vapreotide in patients with cirrhosis and variceal bleeding has shown a significant improvement in bleeding control and, in the subset of patients with significant bleeding, a significant reduction in mortality.

In addition, a meta-analysis of four randomized studies has shown a significant improvement in bleeding control. Vapreotide administrated via the intravenous route is simple to use, with practically no contraindications and few, usually minor, side effects.

Application: The immediate release formulation of Sanvar, a somatostatin analogue, is used in the treatment of acute esophageal variceal bleeding (EVB). Sanvar is used prior to endoscopic intervention to control haemorrhage and prevent re-bleeding during the critical five days following the onset of bleeding.

EVB is a life threatening condition and the mortality rate is high (about 15% to 25%) in the first six weeks following the haemorrhage. EVB is the cause of about 70% of gastro-intestinal bleeding in patients suffering from liver cirrhosis. Sanvar (vapreotide acetate) is a synthetic octapeptide analogue of the naturally-occurring somatostatin hormone.

It has similar pharmacological properties to native somatostatin, but exhibits a longer duration of action. It is the only somatostatin analogue to have demonstrated statistically significant benefits in the early treatment of EVB in association with endoscopic therapy, in a placebo-controlled clinical study (Calès et al.

New England Journal of Medicine, 2001). Control of bleeding with survival at five days was achieved more often with Sanvar (p=0.021) than with placebo. Additional Phase III trials have been completed in Europe in this indication.

Sanvar can be stored at room temperature, an advantage over other products requiring refrigeration, allowing immediate administration, a key benefit in a life-threatening situation. The product has been granted orphan drug status in the U.S., where there is currently no FDA approved treatment for this indication.

Specifications : Product name Vapreotide Acetate Appearance White Powder Assay 98% Molecular formula C57H70N12O9S2 Molecular weight 1131.37 Package 2mg/vial or as your request Shipping Fast and secure shipping by DHL,EMS,UPS,TNT, FedEx..

Shipping leading time Within 12 hours after receiving the payment Payment Terms Western Union, Money Gram , T/T, PayPal Price Negotiable